Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Altimmune, Inc. ALT

Healthcare — Biotechnology
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total buys
0.37
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — 3 2 — 2 3 — — — 1 —
Sell — — — — — — — — — — — —
Insider Ownership
0.95%

Capital & Financial Ratios

Market Cap
636.08
Revenue
0.05
Net Income
(91.76)
Free Cash Flow
(76.56)
Net Debt
(291.58)
Current Ratio
26.78
Debt/Equity
0.07
P/E ratio
0.00
P/S ratio
13,061.69
P/B ratio
1.27
Past 5Y EPS Growth
3.48%
This Y EPS Growth
41.44%
Next Y EPS Growth
(9.41%)
Next 5Y EPS Growth
14.12%
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
—
total individual payouts
2023 ‡‡‡
2022 ‡‡‡
2021 ‡‡‡
2020 ‡‡‡‡
2019 ‡‡‡‡
2018 ‡‡‡‡
2017 2.91
—
2016 ‡‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 197.86 131.93 273.50 326.32
Receivables 4.85 3.12 1.74 3.34
Inventory — — — —
Other — — — —
209.63 137.25 278.19 334.82
2023 2024 2025 Q'26
Payables 2.07 0.21 2.72 1.27
ST’ Debt — — — —
Other — — — —
12.14 10.47 15.00 12.50
in millions of $

Compound Annual Growth

10y 5y 3y
Sales ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡
Cash Flow ‡‡‡ ‡‡‡ ‡‡‡
Earnings ‡‡‡ ‡‡‡ ‡‡‡
Book Value ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 — — — —
—
’25 0.01 0.01 0.01 0.03
0.04
’24 0.01 0.01 0.01 0.01
0.02
’23 0.02 0.01 0.36 0.04
0.43
’22 0.03 0.01 0.00 (0.11)
(0.07)
’21 0.84 0.14 0.16 3.28
4.41
’20 2.21 0.72 2.94 2.31
8.19
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 (20.94) (24.22) — —
—
’25 (16.84) (19.35) (11.90) (19.45)
(67.53)
’24 (16.36) (18.11) (27.12) (18.26)
(79.85)
’23 (19.41) (19.38) (20.49) (16.53)
(75.81)
’22 (13.53) (16.70) (15.05) (17.31)
(62.59)
’21 (19.57) (18.93) (17.77) (21.97)
(78.24)
’20 (4.35) (7.17) (9.50) (13.28)
(34.31)
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 (20.96) (24.25) — —
—
’25 (16.84) (19.36) (11.90) (19.45)
(67.55)
’24 (16.36) (18.11) (27.12) (18.26)
(79.85)
’23 (19.46) (19.38) (20.49) (16.53)
(75.86)
’22 (13.53) (16.72) (15.11) (17.34)
(62.71)
’21 (23.84) (26.70) (17.89) (22.12)
(90.55)
’20 (4.38) (7.25) (9.58) (13.43)
(34.65)
in millions of $

EPS

Mar Jun Sep Dec Year
’26 (0.18) (0.12) — —
—
’25 (0.26) (0.27) (0.21) (0.27)
(1.00)
’24 (0.34) (0.35) (0.32) (0.33)
(1.34)
’23 (0.40) (0.32) (0.39) (0.54)
(1.66)
’22 (0.44) (0.42) (0.48) (0.43)
(1.81)
’21 (0.38) (0.60) (0.81) (0.57)
(2.35)
’20 (0.26) (0.94) (0.54) (0.17)
(1.91)

Target Price Range

High
‡‡‡‡‡
‡‡‡‡
Average
‡‡‡‡‡
‡‡‡‡
Low
‡‡‡‡‡
‡‡‡‡

Recommendation Rating

1.3
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
— ‡‡‡‡ ‡‡‡ ‡‡‡‡ ‡‡‡ ‡‡‡ 3.83 2.09 5.28 2.90 — — —
Low Price
— ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ 23.49 17.17 14.84 7.83 — — —
High Price
‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ 52 59 59 57 — — —
Employees
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.00 0.01 0.00 0.00 — — —
Revenue/Emp
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.07) 0.43 0.02 0.04 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 100.00% 100.00% 100.00% 100.00% — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (84.91) (88.45) (95.06) (88.77) ‡‡‡‡‡ — —
EBT
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 124,867.65% (20,762.21%) (475,295.00%) (216,521.95%) ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (84.71) (88.45) (95.06) (88.09) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.20) 10.43 (3.61) (1.75) — — —
Depreciation
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.00 0.01 0.00 0.00 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1.81) (1.66) (1.34) (1.00) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1.33) (1.42) (1.12) (0.77) — — —
Cash Flow/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.00 0.00 0.00 0.00 ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1.34) (1.42) (1.12) (0.77) — — —
Free CF/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 3.95 3.65 1.74 2.55 — — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 46.93 53.25 71.00 88.10 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00 0.00 0.00 0.00 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
PE Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.00 1,314.92 25,596.73 6,914.26 ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 3.96 2.89 4.15 1.41 ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (8,083.28) 852.32 19,039.48 1,724.56 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
EV/Sales
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (8.74) (4.77) (4.75) (1.17) — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (62.59) (75.81) (79.85) (67.53) ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.13) (0.05) — (0.01) ‡‡‡‡‡ ‡‡‡‡‡ —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (62.71) (75.86) (79.85) (67.55) ‡‡‡‡‡ — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 175.76 197.48 126.79 263.20 — — —
Working Cap'
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.12 — — 34.29 — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (183.79) (197.86) (131.93) (239.21) — — —
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 185.29 194.10 123.51 224.89 — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (39.79%) (42.36%) (54.33%) (42.03%) ‡‡‡‡‡ — —
ROA
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (3,648.54%) 0.00% 0.00% 0.00% — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (44.07%) (46.63%) (59.86%) (50.57%) ‡‡‡‡‡ — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

Altimmune (ALT) is charging ahead in the booming obesity and MASH markets with pemvidutide, its dual GLP-1/glucagon agonist that delivered stunning 15.6% placebo-adjusted weight loss in Phase 2b MOMENTUM trials—rivaling early semaglutide results and showcasing superior liver fat reduction. As Phase 3 trials kick off in 2025 with data eyed for 2027, this clinical-stage biotech is poised for a potential inflection point, trading at depressed early 2026 levels amid a history of revenue droughts, heavy cash burn, and dilution-fueled survival.

Despite ballooning losses and a shrinking cash runway, insiders are betting big with clustered buys totaling over $185K in late 2025 and early 2026, signaling undervaluation post-Phase 3 initiation news. A robust net cash position and negligible debt provide breathing room, while Wall Street’s targets scream upside: 165% to 520% potential, fueled by explosive 2027 revenue projections and buyout buzz akin to Viking Therapeutics’ surge.

Pemvidutide’s edge could spark partnerships or commercialization by 2029, reversing years of biotech volatility and turning binary risks into blockbuster rewards—making ALT a high-octane speculative play with 2-3x potential on trial hits.

Read full commentary →

Altimmune, Inc. (ALT) Latest News

News by impact score

Fine-tune

11 Sep

3 , 11:30 AM
Altimmune (ALT) shares rose 14.2% since the last earnings report, driven by positive market reaction to reported results and outlook. Post-earnings stock gains reflect moderate investor reassessment of financial performance and near-term prospects.

7 Sep

4 , 10:27 PM
Altimmune advances three liver disease trials simultaneously. Concurrent progress on three liver trials signals major pipeline momentum likely to shift investor views and company trajectory.

13 Aug

3 , 12:14 PM
Altimmune posted a narrower Q2 loss than expected while Pemvidutide clinical studies remain the central focus for the company. Narrower loss signals better-than-forecast cash burn and Pemvidutide progress may support modest re-rating of the stock.

12 Aug

4 , 7:03 PM
Altimmune Inc highlighted advancements in its MASH and AUD pipelines during the Q2 2026 earnings call. Pipeline progress in MASH and AUD directly strengthens Altimmune's development path and market position.

3 www.marketbeat.com, 10:05 AM
Altimmune held its Q2 earnings call and released highlights on financial results, pipeline updates, and operational progress. Q2 earnings data can shift near-term sentiment and valuation but rarely redefine long-term strategy.

3 transcript app.moby.co, 8:30 AM
Altimmune, Inc. held its Q2 2026 earnings call covering quarterly financial results, pipeline progress and company outlook. Earnings calls deliver financial results and guidance that affect near-term stock performance.

3 , 7:30 AM
Altimmune, Inc. reported second quarter 2026 financial results and issued a business update. Quarterly results and updates can shift near-term investor views on operations and pipeline progress.

3 Aug

4 , 8:00 AM
Altimmune initiates PERFORMA Phase 3 trial of Pemvidutide in MASH patients. Phase 3 trial start for lead asset advances regulatory path and commercialization prospects.

28 Jul

4 stocktwits.com, 2:42 PM
Altimmune stock reversed early gains after positive alcohol use trial results, though Wall Street and retail investors dismissed the selloff. Positive alcohol use trial data expands pipeline with new indication and can drive long-term valuation shifts.

4 www.marketbeat.com, 10:04 AM
Altimmune’s pemvidutide met its primary endpoint in a Phase II trial for alcohol use disorder. Positive Phase II data expands pemvidutide pipeline value and supports later-stage advancement.

4 stocktwits.com, 8:33 AM
Altimmune’s therapy for alcohol use disorder met primary endpoint. Stock rose 10%. Positive trial outcome marks key clinical milestone that can accelerate development and lift valuation.

4 investorshub.advfn.com, 8:22 AM
Altimmune shares jumped after positive Phase 2 trial results for its alcohol use disorder treatment. Positive Phase 2 results expand pipeline into large alcohol use disorder market and drive immediate stock gains.

4 , 7:00 AM
Altimmune announces positive topline results from RECLAIM Phase 2 trial of pemvidutide in alcohol use disorder. Positive phase 2 data in alcohol use disorder broadens pemvidutide addressable market and strengthens company pipeline outlook.

5 Jul

3 , 6:08 PM
Leerink identifies Altimmune (ALT) as an attractive investment opportunity in the MASH therapeutics market. Positive Leerink coverage on ALT's MASH positioning may lift near-term sentiment and valuation without altering core fundamentals.

17 Jun

4 , 11:16 AM
Altimmune could strengthen its MASH therapy case via Pemvidutide’s broader metabolic data. Pemvidutide metabolic data has potential to materially improve Altimmune’s MASH positioning and investor outlook.

10 Jun

4 www.marketbeat.com, 9:05 AM
Altimmune outlines Phase 3 plans for pemvidutide in MASH while awaiting upcoming AUD data. Phase 3 advancement of lead candidate pemvidutide in MASH marks major clinical milestone with potential to shift company trajectory and sentiment.

8 Jun

4 Zacks, 12:09 PM
Altimmune (ALT) stands at the forefront of dual agonist development targeting liver disease amid sector growth. ALT gains strategic positioning in expanding dual agonist liver disease treatments that can shift market trajectory.

4 Zacks, 12:06 PM
Altimmune advances Pemvidutide development targeting MASH, AUD and ALD indications with upcoming clinical catalysts that could drive pipeline expansion and revenue growth. Pemvidutide's multi-indication setup in large unmet markets positions Altimmune for major clinical and commercial expansion.

3 Zacks, 11:53 AM
Altimmune stock potential evaluated ahead of key 2026 catalysts that could shape investment decisions. 2026 catalysts may moderately influence Altimmune financial trajectory and investor sentiment.

4 Jun

4 www.marketbeat.com, 11:08 PM
Altimmune highlights Pemvidutide progress ahead of Phase 3 MASH trial. Pemvidutide Phase 3 start marks major pipeline advance that can shift Altimmune valuation and trajectory.

28 May

4 GlobeNewswire, 11:00 AM
Altimmune's Pemvidutide demonstrates significant metabolic improvements in MASH patients from 48-week IMPACT Phase 2b trial data presented at EASL 2026. Positive Phase 2b data for lead MASH candidate materially strengthens development path and investor outlook.

27 May

4 GlobeNewswire, 8:00 AM
New IMPACT Phase 2b data shows pemvidutide delivering concurrent gains across multiple non-invasive markers plus qFibrosis-measured fibrosis regression in MASH, presented at EASL 2026. Positive Phase 2b MASH data with fibrosis regression can materially lift ALT valuation and partnering prospects.

22 May

3 Zacks, 12:14 PM
Altimmune stock offers strong upside potential from its advancing clinical pipeline in obesity and NASH treatments, upcoming data readouts, and expanding market opportunities that support near-term growth. Positive stock recommendation highlights upcoming catalysts expected to produce moderate investor interest without fundamentally reshaping company trajectory.

13 May

4 GuruFocus.com, 7:01 PM
Altimmune Inc (ALT) Q1 2026 earnings call highlights strong cash position and strategic initiatives amid clinical progress. Strong cash position and strategic updates signal major advancements in pipeline and financial stability for ALT.

4 transcript www.fool.com, 4:59 PM
Altimmune (ALT) released Q1 2026 earnings call transcript covering financial results, pipeline updates, and forward-looking guidance. Q1 2026 earnings transcript discloses financial performance, clinical progress, and strategic plans with potential to drive significant stock volatility and trajectory shifts.

4 app.moby.co, 4:45 PM
Altimmune, Inc. released Q1 2026 earnings call summary detailing financial results, pipeline updates, and forward guidance. Q1 earnings call summary discloses financial performance and strategic outlook, significantly influencing investor sentiment and stock trajectory.

4 transcript Benzinga, 9:44 AM
Altimmune, Inc. (ALT) Q1 2026 earnings call transcript released, detailing financial results, pipeline updates on obesity drug pemvidutide, clinical trial progress, revenue guidance, and management Q&A. Q1 2026 earnings transcript covers financials, pemvidutide Phase 3 plans, and cash runway, likely driving major shifts in investor sentiment and stock performance.

3 www.marketbeat.com, 10:07 AM
Altimmune's Q1 earnings call highlights financial results, pipeline progress on pemvidutide for obesity, cash position of $149 million, and plans for Phase 2b data readout mid-2024. Q1 earnings reveal moderate updates on finances and clinical milestones that may influence near-term sentiment without fundamentally altering trajectory.

3 investorshub.advfn.com, 9:29 AM
Altimmune shares climbed after first-quarter loss beat expectations. Beating Q1 loss expectations triggered share price gains and boosted short-term investor sentiment.

3 GlobeNewswire, 7:30 AM
Altimmune, Inc. (ALT) announced first quarter 2026 financial results and business update. Quarterly financial results and business updates moderately influence financial performance and investor sentiment.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us